Evidence map›Paper›PMID 40114782›Full record

ArticleBrain communications2025

Higher plasma neurofilament-light chain concentration in drug-resistant epilepsy.

Sarah Akel, Markus Axelsson, Fredrik Asztely, Henrik Zetterberg, Johan Zelano

Abstract read
In one paragraph

Article in Brain communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Sarah AkelDepartment of Clinical Neuroscience, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Gothenburg 41345, Sweden.ORCID https://orcid.org/0000-0003-3806-8724
Markus AxelssonDepartment of Clinical Neuroscience, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Gothenburg 41345, Sweden.
Fredrik AsztelyDepartment of Clinical Neuroscience, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Gothenburg 41345, Sweden.
Henrik ZetterbergDepartment of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Mölndal 43180, Sweden.ORCID https://orcid.org/0000-0003-3930-4354
Johan ZelanoDepartment of Clinical Neuroscience, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Gothenburg 41345, Sweden.ORCID https://orcid.org/0000-0001-9445-4545

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Drug-resistant epilepsy is the most severe form of epilepsy and is frequently associated with cognitive decline. Whether drug-resistant epilepsy results in neurodegeneration or other types of brain injury is not known, and early detection of detrimental clinical trajectories would be clinically very useful. Blood biomarkers of brain injury reflect neurodegeneration or brain injury in several brain diseases but have not been extensively studied in epilepsy. We investigated a panel of such markers in a large epilepsy cohort with an emphasis on assessing differences between drug-resistant and monotherapy-controlled epilepsy. Blood neurofilament light, glial fibrillary acidic protein, total tau, S100 calcium-binding protein B and neuron-specific enolase concentrations were measured in 444 patients (aged ≥ 18 years) with epilepsy participating in a prospective regional Biobank study in Västra Götaland (Sweden). Multiple linear regression assessed associations between clinical variables and marker levels. Levels were then compared between patients with drug-resistant epilepsy (

Indexed as

blood-based biomarkersbrain injurydrug-resistant epilepsyneurodegeneration

Identifiers

PMID40114782
PMCPMC11925020

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.